Brian Kim: Difelikefalin for Pruritus in Atopic Dermatitis
Touch Medical Media coverage of data presented at EADV 2021:
It was a pleasure to meet up with Dr Brian Kim (Washington University School of Medicine, St. Louis, MO, USA) to talk about the use of difelikefalin in treating pruritus associated with atopic dermatitis (AD).
His presentation entitled ‘Oral Difelikefalin Reduces Pruritus in Atopic Dermatitis’ was given at the EADV 30th Congress, 29 Sep – 2 Oct 2021.
Questions
- Could you tell us a little about oral difelikefalin and the rationale for its use in patients with AD and pruritus? (0:17)
- What was the design of the KARE Phase II study and how were patients stratified? (1:19)
- What were the efficacy endpoints and how well were they achieved? (2:32)
- On the basis of these findings, where do you see difelikefalin sitting in the treatment paradigm for pruritus? (2:55)
Disclosures: Dr Brian Kim has acted as a consultant for AbbVie, AstraZeneca, Cara Therapeutics, Galderma, GlaxoSmithKline, LEO Pharma, Eli Lilly, Pfizer, Regeneron, Sanofi and Trevi Therapeutics and undertaken contracted research for Cara Therapeutics and LEO Pharma.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the EADV’s 30th Congress, 29 Sep – 2 Oct 2021.
This content was developed by Touch Medical Media and is not affiliated with the European Academy of Dermatology & Venereology (EADV) or the congress.
